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1380Objective: Hepcidin regulates iron absorption and recycling and is central to host defense, protection from re-
active iron species, and a biomarker of iron-related pathophysiology. We assessed the value of hepcidin mea-
sured preoperatively for the prediction of in-hospital mortality and renal outcomes.
Methods: We studied 100 adult patients undergoing cardiac surgery in the control arm of a randomized, con-
trolled trial. Plasma and urine were sampled before induction of anesthesia, and hepcidin-25 was quantified
by competitive enzyme-linked immunoassay. Renal outcomes were acute kidney injury defined by risk, injury,
failure, loss of function, end-stage renal disease (RIFLE) classification and need for renal replacement therapy.
Variables with the potential to influence hepcidin expression were investigated.
Results: Low preoperative hepcidin concentration in urine (median, 15.3 ng/mL; 25-75 percentiles, 0-129.1)
and plasma (median, 49.2 ng/mL; 25th-75th percentile, 0-52.2) predicted mortality (area under the curve–re-
ceiver operating characteristic [AUC-ROC] for urine hepcidin, 0.89; 95% confidence interval, 0.73-0.99; cutoff,
130 ng/mL; sensitivity, 73%; specificity, 100%; and AUC-ROC for plasma hepcidin, 0.90; 95% confidence in-
terval, 0.80-0.99; cutoff, 55 ng/mL; sensitivity, 83%; specificity, 100%). Survivors had median preoperative
hepcidin concentrations of 325.3 ng/mL (25th-75th percentile, 120-770.1 ng/mL) in urine and 113.1 ng/mL
(25th-75th percentile, 77.7-203.1 ng/mL) in plasma. Preoperative serum creatinine did not predict mortality
(AUC-ROC, 0.50; 95% confidence interval, 0.10-0.94). Furthermore, preoperative urine, plasma hepcidin,
and serum creatinine did not distinguish patients requiring postoperative renal replacement therapy from those
without (urine: AUC-ROC, 0.62; 95% confidence interval, 0.38-0.86; plasma: AUC-ROC, 0.63; 95%
confidence interval, 0.34-0.91; serum creatinine: AUC-ROC, 0.61; 95% confidence interval, 0.22-0.99).
Preoperative renal function and hemoglobin did not correlate with hepcidin indices whereas plasma markers
of inflammation did.
Conclusions: Low preoperative hepcidin concentration might be a risk factor for in-hospital mortality. Find-
ings should be validated in larger patient cohorts with a greater number of events. (J Thorac Cardiovasc Surg
2013;145:1380-6)Cardiac surgery with cardiopulmonary bypass (CPB) is one
of the most common major surgical procedures worldwide
and improves quality of life and long-term survival.1 How-
ever, CPB facilitates labile iron toxicity through hemolysis
and generation of oxidoinflammation.2,3 Iron is an essential
trace element for molecules sensing, transporting, and
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Novel biomarkers involved in central iron homeostasis
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Abbreviations and Acronyms
AKI ¼ acute kidney injury
CI ¼ confidence interval
CKD ¼ chronic kidney disease
CPB ¼ cardiopulmonary bypass
CRP ¼ C-reactive protein
eGFR ¼ estimated glomerular filtration rate
IL ¼ interleukin
RRT ¼ renal replacement therapy
Haase-Fielitz et al Perioperative Managementinfluenced by iron loading, hypoxia, or inflammation.5-7
Hepcidin is a low-molecular weight peptide (2.78 kD); it
passes through the glomerular membrane and is reabsorbed
and degraded in the proximal tubules with only a small frac-
tion (3-5%) of the filtered hepcidin passing intact into
urine.8 Therefore, hepcidin concentrations in biofluid may
indicate disorders of iron metabolism and may be associ-
ated with prognosis. Recently, several work groups found
early postoperative hepcidin to be useful in predicting pro-
tection from acute kidney injury (AKI) after CPB.9-12 These
studies provide further support for the role of labile iron-
associated reactive oxygen species in the pathophysiology
of AKI after the use of CPB in light of the demonstrated
utility of other iron-associated protein biomarkers (eg, neu-
trophil gelatinase–associated lipocalin, liver-type fatty
acid–binding protein, cystatin C) for the prediction of tubu-
lar damage.2 The need for improved preoperative risk pre-
diction, the central biologic role of hepcidin, and the
importance of CPB in augmenting labile iron-induced organ
toxicity suggest hepcidin may have value as a biomarker for
risk stratification.
In this study, we aimed (1) to assess the predictive value
of preoperative urine and plasma hepcidin concentration for
in-hospital mortality, need for renal replacement therapy
(RRT) initiation, and the development of AKI; and (2) to in-
vestigate modifiers of hepcidin, including preoperative
chronic kidney disease (CKD), concentrations of hemoglo-
bin, and markers of inflammation.P
MMETHODS
Patient Population
For the purpose of the study, we took advantage of the control arm of
a multicenter, randomized, controlled trial (N ¼ 100) at its German study
center (www.clinicaltrials.gov, NCT00672334). This study compared peri-
operative sodium bicarbonate versus placebo (sodium chloride 0.9%) for
the prevention of AKI and the exploration of renal biomarkers in patients
at increased renal risk undergoing cardiac surgery necessitating the use
of CPB.
CKD was defined as a preoperative estimated glomerular filtration rate
(eGFR) <60 mL/min/1.73 m2.13 eGFR was estimated using the CKD
Epidemiology Collaboration equation14 using serum creatinine values
standardized to isotope dilution mass spectroscopy. RRT was initiated if
the patient fulfilled at least 1 of the following clinical criteria: oliguria
(urine output, <100 mL/>6 hours) unresponsive to fluid resuscitationThe Journal of Thoracic and Carmeasures, hyperkalemia (K> 6.5 mmol/L), severe acidosis (pH< 7.2),
or clinically significant organ edema (eg, lung) in the setting of AKI.
Samples of ethylenediamine tetraacetic acid–plasma and urine were ob-
tained simultaneously directly after insertion of an arterial line before in-
duction of anesthesia. Aliquots of plasma and urine were stored frozen at
80C immediately after collection and centrifugation, and were kept fro-
zen on dry ice during transport. Patients were recruited between January
2009 and June 2010. The local institutional review board approved this
study and written informed consent was obtained from each patient includ-
ing the investigation of novel renal biomarkers. The study was carried out
in compliance with the Helsinki Declaration.
Data Collection and Outcome Definition
Demographic and clinical data were collected at baseline and during the
patient’s stay in the intensive care unit. Serum creatinine was measured at
baseline and daily within the first postoperative week and, if required, until
hospital discharge. AKI was defined based on the baseline-to-peak serum
creatinine increase (>50%) or urine output decrease (<0.5 mL/kg/hour
for at least 6 hours) during the first 7 postoperative days using the risk, in-
jury, failure, loss of function, end-stage renal disease (RIFLE) consensus
definition.15 The value of this AKI definition has been reported previ-
ously.16,17 As mentioned, RRT was initiated if the patient fulfilled at
least 1 of the following clinical criteria: oliguria (urine output,<100 mL/
>6 hours) unresponsive to fluid resuscitation measures, hyperkalemia (K
>6.5 mmol/L), severe acidosis (pH<7.2), or clinically significant organ
edema (eg, lung) in the setting of renal failure. Mortality was defined as
in-hospital death during the primary postoperative hospital stay. The
Strengthening the Reporting of Observational Studies in Epidemiology
recommendations18 for reporting observational studies were used.
Biochemical Analysis
Co-investigators performing hepcidin assays (M.W., V.O.) were blinded
to patient details and outcomes. Human urine and plasma hepcidin-25 iso-
forms were measured by competitive enzyme-linked immunoassay in du-
plicate, as described previously.8 The lower limit of hepcidin detection
was 5.5 ng/mL. The median coefficient of variation was<10% for intra-
assay precision and 6% for interassay reproducibility. Urine hepcidin ad-
justed to urine creatinine was calculated and expressed as nanograms hep-
cidin per milligrams creatinine. Serum creatinine assays were carried out
using the modified Jaffe method. Fractional excretion of hepcidin (ie, the
proportion of filtered hepcidin that appears in urine) was calculated by
the following formula:
FEhepcidin ¼

Uhepcidin

3

Plcreat

Plhepcidin

3

Ucreat

3100%
where FE is the fractional excretion, Uhepcidin is the urine hepcidin concen-
tration, Plhepcidin is the plasma hepcidin concentration, Plcreat is the plasma
creatinine concentration, and Ucreat is the urine creatinine concentration.
In preoperative samples, we measured interleukin (IL) 6 in urine and
plasma by means of enzyme-linked immunosorbent assay (IL-6; ECLIA,
Roche Diagnostics, Mannheim, Germany) or immunoturbidimetry for C-
reactive protein (CRP; ECLIA, Roche Diagnostics) in plasma. The coeffi-
cient of variation for each assay was<10%.
Statistics
Statistical analysis was performed using SPSS 16.0 (SPSS Inc, Chicago,
Ill) and MedCalc 11.5 (Mariakerke, Belgium). Categorical data were re-
ported as percentageswith the 95% confidence interval (CI) of themean per-
centage, and compared using the Fisher exact test. After testing for normal
distribution, continuous data were reported as median with 25th to 75th per-
centiles, and nonparametric datawere compared using theMann-WhitneyU
test. We used nonparametric bivariate correlation and report Spearman cor-
relation coefficients. The ability of hepcidin to predict in-hospital mortality,
RRT, or AKI was assessed by plotting receiver operating characteristicdiovascular Surgery c Volume 145, Number 5 1381
TABLE 1. Preoperative characteristics of patients
Variables Died (n ¼ 3) Survived (n ¼ 97) P value RRT (n ¼ 5) No RRT (n ¼ 95) P value
Age, y; median (25th-75th percentile) 71 (69-75) 68 (57-74) .41 75 (71-77) 68 (56-73) .05
Female, n (%) 2 (67) 31 (32) .25 2 (40) 31 (33) >.99
Weight, kg; median (25th-75th percentile) 75 (59-85) 79 (67-89) .55 80 (62-101) 78 (67-87) .76
Preoperative chronic kidney disease, n (%) 2 (67) 24 (2) .17 3 (60) 23 (24) .11
Serum creatinine, mmol/L; median
(25th-75th percentile)
88 (53-141) 87 (78-106) >.99 121 (63-190) 87 (78-105) .38
Urine creatinine, g/24 hours; median
(25th-75th percentile)
0.92 (0.39-1.08) 1.14 (0.57-1.77) .33 0.93 (0.55-1.64) 1.14 (0.57-1.74) .68
Hemoglobin, g/dL; median (25th-75th percentile) 11.4 (11.3-14.3) 12.6 (11.3-14.0) .82 11.2 (9.1-12.9) 12.6 (11.3-14.0) .10
Preoperative LVEF<35%, n (%) 2 (67) 9 (9) .031 1 (20) 10 (11) .45
Arterial hypertension, n (%) 2 (67) 71 (73) >.99 4 (80) 69 (73) >.99
Hypercholesterolemia, n (%) 3 (100) 61 (63) .55 3 (60) 61 (63) >.99
Chronic obstructive pulmonary disease, n, (%) 0 (0) 11 (11) >.99 1 (20) 10 (11) .45
Diabetes mellitus, n (%)* 2 (67) 18 (19) .10 1 (20) 19 (20) >.99
Atrial fibrillation, n (%)y 2 (67) 28 (29) .21 3 (60) 27 (28) .16
Peripheral vascular disease, n (%) 1 (33) 20 (21) .52 0 (0) 21 (22) .58
ACE-inhibitors/ATRB, n (%) 3 (100) 51 (52) .25 4 (80) 50 (53) .37
b-blocker, n (%) 3 (100) 69 (70) .56 4 (80) 68 (72) >.99
Statins, n (%) 2 (67) 51 (52) >.99 3 (60) 50 (53) >.99
Diuretics, n (%) 3 (100) 56 (58) .27 4 (80) 55 (58) .40
RRT, Renal replacement therapy; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; ATRB, angiotensin II receptor blocker. *Diabetes mellitus is
defined as patients with diabetes on medication (insulin or oral antidiabetics). yAtrial fibrillation (AF) was defined as paroxysmal, persistent, or permanent AF with first time
episodes of AF counted as no AF.
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M(ROC) curves, and further reported as area under the curve (AUC)with 95%
CIs. An AUC-ROC value of>0.7 was taken to indicate a reasonable perfor-
mance and>0.8 indicated a good biomarker performance.19 ROC optimal
cutoff values with a statistically significant AUC were defined as the point
thatmaximized the combination of sensitivity and specificity. Statistical sig-
nificance was denoted by 2-sided P values of<.05.RESULTS
Patient Characteristics
Preoperative characteristics are presented in Tables 1
and 2. Survivors or patients who did not require RRT
were younger, more likely to be male, had fewer preopera-
tive comorbidities including CKD and atrial fibrillation, and
a trend to a shorter duration of CPB (Tables 1 and 2). Type
of operation did not differ among all patients. Survivors and
those who did not require RRT received more fluids; how-
ever, lower volumes of blood transfusion and doses of furo-
semide, and had a preserved diuresis within the first 24
hours postoperatively (Table 2). In our cohort, all patients
who died developed AKI, with 1 patient requiring RRT.
Two patients died of cardiogenic shock and 1 died of sepsis.
Patients who died or required RRT had a 2.5-day longer stay
in the intensive care (Table 2). RRT was initiated in 3 pa-
tients as a result of AKI and in 2 patients as a result of anuria
for<6 hours and preoperative CKD.Preoperative Value of Hepcidin for In-Hospital
Mortality
Survivors had a 20-times higher median preoperative
urine hepcidin concentration compared with nonsurvivors1382 The Journal of Thoracic and Cardiovascular Sur(P ¼ .020; Figure 1, A). This difference translated in an
AUC-ROC for the prediction of postoperative mortality of
0.89 with a cutoff of 130 ng/mL, a sensitivity of 73%,
and a specificity of 100% (Figure 2, A). They also had
2-times higher preoperative plasma hepcidin concentrations
compared with nonsurvivors (P¼ .013; Figure 1, B). Preop-
erative plasma hepcidin concentration was a good predictor
of mortality, with an AUC-ROC of 0.90, a cutoff of 55 ng/
mL, a sensitivity of 83%, and a specificity of 100%
(Figure 2, A). The predictive value for mortality was in
the same magnitude for preoperative fractional hepcidin
excretion (AUC-ROC, 0.90; 95% CI, 0.77-0.99; cutoff,
1.31%; sensitivity, 81%; specificity, 100%) and for
preoperative urine hepcidin adjusted to urine creatinine
(AUC-ROC, 0.89; 95% CI, 0.78-0.99; cutoff, 120 ng/mg;
sensitivity, 77%; specificity, 100%). Both preoperative
serum creatinine and eGFR did not predict mortality
(AUC-ROC, 0.50; 95% CI, 0.10-0.94 and AUC-ROC,
0.62; 95% CI, 0.25-0.98, respectively.
Preoperative Value of Hepcidin for Renal Outcome
Preoperative urine and plasma hepcidin concentrations
were similar in patients requiring RRT or not (P ¼ .37
and P¼ .35, respectively; Figure 3, A and B). Both markers
(Figure 2, B) as well as serum creatinine concentration or
eGFR could not discriminate patients requiring postopera-
tive RRT (urine hepcidin AUC-ROC, 0.62; plasma hepcidin
AUC-ROC, 0.63; fractional hepcidin excretion AUC-ROC,
0.51; 95% CI, 0.20-0.77; urine hepcidin adjusted to urine
creatinine AUC-ROC, 0.64; 95% CI, 0.37-0.91; serumgery c May 2013
TABLE 2. Interventions and outcomes
Variables Died (n ¼ 3) Survived (n ¼ 97) P value RRT (n ¼ 5) No RRT (n ¼ 95) P value
CABG surgery, n (%) 1 (33) 18 (19) .47 1 (20) 18 (19) >.99
Valve surgery, n (%) 1 (33) 49 (51) >.99 2 (40) 48 (51) >.99
CABG and valve surgery, n (%) 1 (33) 23 (24) .57 2 (40) 22 (23) .59
Thoracic aortic surgery, n (%) 0 (0) 7 (7) >.99 0 (0) 7 (7) >.99
Previous cardiothoracic operation, n (%) 0 (0) 28 (29) .56 0 (0) 28 (29) .32
Duration of bypass, min; median
(25th-75th percentile)
131 (125-274) 118 (91-159) .18 125 (107-217) 119 (91-158) .29
Within the first 24 hours postoperatively
Fluid input, mL; median (25th-75th percentile)* 2810 (1030-7360) 8130 (6520-9640) .036 5500 (3180-7290) 8160 (6590-9680) .021
Urine output, mL; median (25th-75th percentile) 3450 (2430-5010) 5170 (4240-6540) .048 4000 (2880-6100) 5150 (4300-6500) .20
Blood transfusion, n (%) 3 (100) 53 (55) .27 4 (80) 52 (55) .38
Blood transfusion, mL; median
(25th-75th percentile)
4250 (500-5900) 250 (0-500) .017 1000 (250-3500) 250 (0-500) .079
Other blood products, mL; median
(25th-75th percentile)y
7550 (0-13,300) 330 (0-1210) .13 2860 (1400-8470) 0 (0-880) .001
Furosemide, n (%) 2 (67) 70 (72) >.99 4 (80) 68 (72) >.99
Furosemide, mg; median (25th-75th percentile) 80 (0-270) 20 (0-40) .25 80 (30-280) 20 (0-40) .023
Vasopressor use, n (%) 2 (67) 67 (69) >.99 4 (80) 65 (68) >.99
Inotrope use, n (%) 3 (100) 56 (58) .27 5 (100) 54 (57) .076
Length of stay in intensive care, hours; median
(25th-75th percentile)
81.1 (74.6-148.7) 26.3 (22.6-70.1) .090 81.1 (35.9-410.9) 26.3 (22.6-71.1) .050
AKI defined by RIFLE, n (%) 3 (100) 6 (6) .001 3 (60) 6 (6) .005
Need for RRT, n (%) 1 (33) 4 (4) .023 — — —
Hospital mortality, n (%) — — — 1 (20) 2 (2) .023
RRT, Renal replacement therapy; CABG; coronary artery bypass grafting; AKI, acute kidney injury; RIFLE, risk, injury, failure, loss of function, end-stage renal disease. *In-
cluding crystalloids and colloids. yIncluding fresh-frozen plasma, platelets, and cryoprecipitates.
Haase-Fielitz et al Perioperative Managementcreatinine AUC-ROC, 0.61; 95% CI, 0.22-0.99; and eGFR
AUC-ROC, 0.66; 95% CI, 0.33-0.98).
Furthermore, preoperatively, patients not developing
AKI presented with nonsignificant higher urine and plasma
hepcidin concentrations compared with patients developing
AKI later (Figure 4). This difference did not translate in
a good predictive value for postoperative AKI (urine hepci-
din AUC-ROC, 0.68; plasma hepcidin AUC-ROC, 0.67;
Figure 2, C). Also, preoperatively, fractional hepcidin ex-
cretion (AUC-ROC, 0.65; 95% CI, 0.46-0.83), urine hepci-
din adjusted to urine creatinine (AUC-ROC, 0.69; 95% CI,
0.51-0.87), serum creatinine (AUC-ROC, 0.56; 95% CI,
0.34-0.78), or eGFR (AUC-ROC, 0.62; 95% CI, 0.42-
0.82) could not predict the development of AKI.P
MRenal Function, Hemoglobin, Inflammation
Markers, and Preoperative Hepcidin
Preoperative eGFR did not correlate with preoperative
urine and plasma hepcidin indices (all Spearman correlation
coefficients<0.20). Results did not change after adjustment
to urine creatinine (Table 3). Baseline eGFR correlated with
plasma markers of inflammation (Spearman-r coefficients
for IL-6,0.40; P ¼ .009 and for CRP,0.34; P ¼ .025)
and with preoperative hemoglobin concentration (Spear-
man-r coefficient, 0.34; P ¼ .001).
Although, patients surviving or not requiring RRT had
a trend for higher preoperative hemoglobin concentrationsThe Journal of Thoracic and Car(Table 1), hemoglobin did not correlate with preoperative
hepcidin indices (Table 3). Preoperative plasma IL-6 and
CRP but not urine IL-6 correlated significantly with frac-
tional hepcidin excretion and urine hepcidin adjusted for
urine creatinine (Table 3).DISCUSSION
In a small pilot study of 100 patients undergoing cardiac
surgery, we found that low preoperative urine and plasma
hepcidin concentrations were predictors of in-hospital mor-
tality, although they had no value as predictors of renal
outcomes. Preoperative eGFR and hemoglobin did not
correlate with hepcidin indices, whereas plasma IL-6 and
CRP did.
Hepcidin represents a principal regulator of extracellular
iron homeostasis in health and disease, and as such is
a promising target for the diagnosis of labile iron-
mediated disorders. There are already several studies
suggesting an important role of hepcidin in modulating
and predicting the course and outcome of inflammation-
mediated diseases. Early postoperative increases in hepci-
din concentrations indicated protection from subsequent
AKI9-12 and malaria-associated mortality.20
Previously, IL-6 was shown to be a prominent systemic
inducer of hepcidin expression.4,5,21,22 Contrary to these
previous observations, we found a weak relationship
between plasma concentrations of inflammatory markersdiovascular Surgery c Volume 145, Number 5 1383
FIGURE 1. Preoperative urine hepcidin (A) and plasma hepcidin (B) con-
centrations in survivors and nonsurvivors. White boxes indicate median
hepcidin concentration in nanograms per milliliter with the 25th to 75th
percentiles in patients who survived the hospital stay (urine: 325.3 ng/
mL; 25th-75th percentile, 120.0-770.1; plasma: 113.1 ng/mL; 25th-75th
percentile, 77.7-203.1). Black boxes indicate median hepcidin concentra-
tion in nanograms per milliliter with 25th to 75th percentiles in those
who died (urine: 15.3 ng/mL; 25th-75th percentile, 0-129.1; plasma:
49.2 ng/mL; 25th-75th percentile, 0-52.2).
FIGURE 2. Area under the curve–receiver operating characteristic analyses
(AUC-ROC) of preoperative urine andplasmahepcidin for in-hospitalmortal-
ity (A), requirement of postoperative renal replacement therapy (RRT) initi-
ation (B) and acute kidney injury (AKI; risk, injury, failure, loss of
function, end-stage renal disease [RIFLE]) (C). CI, Confidence interval.
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Mand hepcidin. Upregulation of hepcidin in IL-6 knockout
mice with chronic inflammation is similar to wild-type
mice, suggesting IL-6-independent pathways of hepcidin
stimulation.4,23 As an alternative explanation, the absent
correlation between urine and plasma hepcidin with
proinflammatory markers might confirm previous results
in which hepcidin is only upregulated under conditions of
overt inflammation22 not expected to occur in our patients
in a preoperative setting.
The association between hepcidin and inflammatory
markers increased when hepcidin indices integrating renal
excretory function markers such as fractional excretion or
adjustment to urine creatinine were used. The observed1384 The Journal of Thoracic and Cardiovascular Surgery c May 2013
FIGURE 3. Preoperative urine hepcidin (A) and plasma hepcidin (B) con-
centrations in patients requiring renal replacement therapy (RRT) and in
those who did not. White boxes indicate median hepcidin concentration in
nanograms per milliliter with 25th to 75th percentiles in patients not requir-
ing RRT. Gray boxes indicate median hepcidin concentration in nanograms
per milliliter with 25th to 75th percentiles in patients with RRT initiation.
FIGURE 4. Preoperative urine and plasma hepcidin concentrations in pa-
tients with acute kidney injury (AKI) and without AKI. White boxes indi-
cate median urine hepcidin concentration in nanograms per milliliter
with 25th to 75th percentiles (no-AKI: median urine hepcidin concentra-
tion, 326.6 ng/mL; 25th-75th percentile, 117.5-692.6; AKI: median urine
hepcidin concentration, 133.6 ng/mL; 25th-75th percentile, 15.2-263.6).
Gray boxes indicate median plasma hepcidin concentration in nanograms
per milliliter with 25th to 75th percentiles (no-AKI: median plasma hepci-
din concentration, 112.2 ng/mL; 25th-75th percentile, 77.6-203.4; AKI:
median plasma hepcidin concentration, 55.2 ng/mL; 25th-75th percentile,
50.0-145.7).
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Mcorrelation of preoperative fractional hepcidin excretion
with CRP indicates microinflammation in our patients.
Therefore, it is possible that postoperatively declining renal
function might potentiate the relationship between inflam-
mation and iron metabolism. Although significant glomeru-
lar hepcidin filtration can be expected, our findings are in
line with Peters and colleagues,24 who recently report that
eGFR is not a major determinant of serum hepcidin-25
levels. Unlike previous studies enrolling patients with
CKD,25,26 we found hepcidin not to be correlated with
preoperative hemoglobin levels.
The findings of our pilot study point toward the potential
usefulness of preoperative hepcidin measurement for risk
assessment. If confirmed, hepcidin might become part of
scoring systems applied before cardiac surgery. They also
suggest the need to study the biology of hepcidin toThe Journal of Thoracic and Carunderstand in greater detail what this marker might tell us
about underlying disturbances in iron metabolism and their
impact on outcome.
A potential mechanism explaining the negative relation-
ship between low preoperative hepcidin concentration and
mortality might be linked to preoperative ‘‘subclinical’’
hypoxia. Hypoxia regulates hepcidin down, causing (free)
iron release into plasma4—an effect that might be potenti-
ated during CPB in affected patients. Misliganded iron
and other reactive substances may contribute to clinically
detectable organ injury.2 All patients who died in hospital
in the current study developed postoperative AKI, which
was detected by low, early postoperative hepcidin concen-
tration, as previously reported.9
Our study has several strengths and limitations. In partic-
ular, the simultaneous measurement or calculation of preop-
erative hepcidin and hepcidin indices and inflammation
markers in a relatively homogenous and well-characterized
patient cohort enabled detection of a biologically plausible
association. However, the number of events was low and
the addition of patients with high hepcidin concentration
(>75th percentile of patients who did not die in hospital)
who present with an unfavorable outcome (in-hospital death)
would have changed the results to borderline or nonsignifi-
cant. Therefore, our study can only serve as a pilot investiga-
tion to test a new research hypothesis in a small number of
subjects. Findings should be validated in larger patient co-
horts with greater number of events, making multivariate
clinical and biochemical score modeling possible, and aim-
ing at improving existing risk prediction scores applied in
cardiac surgery.diovascular Surgery c Volume 145, Number 5 1385
TABLE 3. Correlation of preoperative variables with preoperative hepcidin indices
Variables
Urine
hepcidin Plasma hepcidin
Urine:plasma
hepcidin ratio
Fractional hepcidin
excretion
Urine hepcidin/urine
creatinine Urine creatinine
eGFR 0.15, P ¼ .15 0.043, P ¼ .67 0.18, P ¼ .11 0.16, P ¼ .12 0.07, P ¼ .51 0.26, P ¼ .010
Hemoglobin 0.13, P ¼ .21 0.06, P ¼ .55 0.14, P ¼ .18 0.09, P ¼ .38 0.01, P ¼ .93 0.28, P ¼ .005
Urine IL-6 0.028, P ¼ .78 0.01, P ¼ .92 0.078, P ¼ .45 0.006, P ¼ .95 0.039, P ¼ .70 0.012, P ¼ .91
Plasma IL-6 0.19, P ¼ .22 0.09, P ¼ .56 0.19, P ¼ .23 0.49, P ¼ .001 0.31, P ¼ .04 0.24, P ¼ .12
CRP 0.22, P ¼ .16 0.18, P ¼ .24 0.16, P ¼ .29 0.43, P ¼ .004 0.33, P ¼ .027 0.19, P ¼ .22
Values denote Spearman r correlation coefficients. eGFR, Estimated glomerular filtration rate; IL, interleukin: CRP, C-reactive protein.
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P
MIn conclusion, low preoperative hepcidin concentrations
are predictive of in-hospital mortality but not of renal out-
comes in patients undergoing cardiac surgery. Further vali-
dation of this finding is now required.
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